Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population

Abstract

BackgroundThe disorder of triglyceride (TG) metabolism leading to hypertriglyceridemia is an independent risk factor for coronary artery disease (CAD). Variants in the apolipoprotein C3 (APOC3) gene were found to be associated with elevated TG levels. The purpose of this study was to investigate the effect of two polymorphisms (1100 C/T and 3238 C/G) of APOC3 on plasma lipid and risk of CAD in a Chinese population.MethodsThe study population consisted of 600 patients with CAD and 600 age- and gender-matched controls. The APOC3 gene polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).ResultsPatients with CAD had a significantly higher frequency of APOC3 3238 GG genotype [odds ratio (OR) =1.64, 95% confidence interval (CI) =1.10, 2.43; P = 0.01] and APOC3 3238 G allele (OR =1.27, 95% CI =1.04, 1.55; P = 0.02) than controls. The findings are still emphatic by the Bonferroni correction. When stratifying by hyperlipidemia, CAD patients with hyperlipidemia had a significantly higher frequency of APOC3 3238 GG genotype (OR =1.73, 95% CI =1.13, 2.64; P = 0.01) than without hyperlipidemia. The APOC3 3238 G allele was significantly associated with increasing plasma TG levels and very-low-density lipoprotein cholesterol (VLDL-C) levels both in cases and controls (P < 0.001).ConclusionsThe APOC3 3238 G allele might contribute to an increased risk of CAD as a result of its effect on TG and VLDL-C metabolism.

Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review

“…Whereas a study in the Chinese Han population suggested that the two genetic variants (T -455C at rs2854116 and C-482 T at rs2854117 ) in the APOC3 were not associated with NAFLD risk, even did not contribute to the inter-individual differences in lipid profiles, insulin resistance, obesity, oxidative stress and susceptibility to NAFLD [ 47 ]. A case–control study found that the APOC3 3238G allele was significantly associated with increasing plasma TG levels and VLDL-C levels and enhanced risk of CAD via lipid metabolism [ 48 ].…”

Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage

“…A systematic review of 20 studies comprising 15,591 participants found that APOC3 Sst I and T-455C polymorphisms might be associated with coronary heart disease risk [ 17 ]. A case–control study suggested that the APOC3 3238 G allele might contribute to an increased risk of coronary artery disease as a result of its effect on TG and VLDL-C metabolism [ 26 ]. A case–control study found that the minor alleles of APOC3 −455 T/C polymorphisms were closely associated with acute coronary syndrome [ 27 ].…”

“…The Bogalusa Heart Study found that APOC3 3238 C/G polymorphisms were associated with higher serum triglyceride levels [ 30 ]. A recent prospective case–control study also found that the APOC3 3238 G allele might contribute to an increased risk of coronary artery disease as a result of its effect on TG and VLDL-C metabolism [ 26 ]. Serum lipid levels may be associated with the risk of ICH [ 10 – 12 ].…”

APOA5 -1131T>C and APOC3 -455T>C polymorphisms are associated with an increased risk of coronary heart disease

“…Several polymorphisms have been found in the APOC3 gene, including C-482T, T-455C, Sst I, and C1100T. Moreover, accumulating evidence suggests that APOA5 -1131T>C and APOC3 -455T>C polymorphisms play a major role in the development of CHD because of their association with increased plasma TGs (Zhang et al, 2011;Zhou et al, 2013;Cui et al, 2014). On the other hand, many studies have reached contradictory conclusions regarding the role of APOC3 and APOA5 variants in CHD (Martinelli et al, 2007;Maasz et al, 2008;Prochaska et al, 2010;Yu et al, 2011).…”